Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Larimar Therapeutics, Inc. (LRMR) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Larimar Therapeutics, Inc. (LRMR) - free report >>
Image: Bigstock
New Strong Buy Stocks for April 12th
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
Celularity Inc. (CELU - Free Report) : This clinical-stage biotechnology company has seen the Zacks Consensus Estimate for its current year earnings increasing 6.4% over the last 60 days.
Celularity, Inc. Price and Consensus
Celularity, Inc. price-consensus-chart | Celularity, Inc. Quote
MoneyGram International, Inc. : This peer-to-peer payments and money transfer services company has seen the Zacks Consensus Estimate for its current year earnings increasing 16.7% over the last 60 days.
MoneyGram International Inc. Price and Consensus
MoneyGram International Inc. price-consensus-chart | MoneyGram International Inc. Quote
Larimar Therapeutics, Inc. (LRMR - Free Report) : This clinical-stage biotechnology company has seen the Zacks Consensus Estimate for its current year earnings increasing 47.8% over the last 60 days.
Larimar Therapeutics, Inc. Price and Consensus
Larimar Therapeutics, Inc. price-consensus-chart | Larimar Therapeutics, Inc. Quote
EQRx, Inc. : This medicine company focused on oncology and immune-inflammatory diseases has seen the Zacks Consensus Estimate for its current year earnings increasing 12.1% over the last 60 days.
EQRx, Inc. Price and Consensus
EQRx, Inc. price-consensus-chart | EQRx, Inc. Quote
Surrozen, Inc. (SRZN - Free Report) : This clinical-stage biotechnology company has seen the Zacks Consensus Estimate for its next year earnings increasing 15.3% over the last 60 days.
Surrozen, Inc. Price and Consensus
Surrozen, Inc. price-consensus-chart | Surrozen, Inc. Quote
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.